Technology Bundle ID
TAB-2395

Potential Use of anti-IgE in the Treatment of Lupus Nephritis

Applications
Linked ID
E-216-2010-0
Lead Inventors
Juan Rivera (NIAMS)
Co-Inventors
Nicolas Charles (NIAMS)
Development Status
  • Early-stage
  • Pre-clinical
Disease Areas
ICs
Systemic lupus erythematosus (SLE) is a multi-organ inflammatory disease characterized by a significant morbidity and mortality related to both disease evolution as well as therapeutic side effects. At least half of SLE patients develop lupus nephritis./>
The inventors have used a Lyn -/- mouse model that develops an autoimmune disease exhibiting some features of human SLE. Using this model the inventors identified basophils and self-reactive IgEs as important components in the development of autoantibody-mediated kidney disease. The inventors found that depletion of basophils or the absence of IgE causes a considerable reduction in autoantibody production and preserves kidney function in the Lyn -/- mice. The inventors' work demonstrates that IgE immune complexes can activate basophils and that removal of self-reactive IgEs that form functional circulating immune complexes prevents kidney disease. Further, the inventors have shown that basophils are contributors to the production of the self-reactive antibodies that cause lupus-like nephritis in the Lyn -/- mice. Accordingly, reducing circulating IgE levels or reducing basophil activation may be of therapeutic benefit.
Commercial Applications
Further research and development of therapeutic approach to treat lupus nephritis.
Competitive Advantages
Current treatment of lupus has not advanced for many years. This finding is of importance for its potential in advancing treatment of the disease.

Request More Info

Licensing Contact: